Immunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases
Immunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases. Our lead program, IMT-009, targets CD161 and is in clinical trials for patients with refractory tumors across a variety of indications including MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer.